Figure 2.
Expression of CRELD2 in Neuro2a cells. Neuro2a cells were treated with or without thapsigargin (Tg, 0.1 μM), tunicamycin (Tm, 1 μg/ml), breferdin A (BFA, 2.5 μg/ml) or serum-deprived medium (serum free, SF) for 8 h (A) and 12 h (B). (C) Neuro2a cells under the serum-deprived medium were treated with Tg, Tm, BFA or vehicle for 12 h. After treatment, secreted CRELD2 (medium) and the indicated proteins in each cell lysate (lysate) were prepared as described in the Materials and methods section. The expression of the indicated mRNA (A) and protein (B,C) was detected by RT-PCR and western blotting analysis as described in the Materials and methods section. Representative data from more than three independent experiments are shown.